Acyclovir: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #150 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Antivirals]] | |||
[[Category:Nucleoside analogs]] | |||
[[Category:Anti-herpesvirus agents]] | |||
Latest revision as of 10:43, 23 May 2026
Acyclovir
Zovirax
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days
Preparations
200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical)
US FDA Max
Indication-specific; high-dose IV regimens for encephalitis or disseminated disease
Pharmacology
Routes
Oral, IV, topical
Onset
Symptom relief within 24-48 hours of starting episodic treatment
Duration
8 hours per oral dose
Half-life
~3 hours; significantly prolonged in renal impairment[1]
Bioavailability
~20% (oral; valacyclovir prodrug raises this to ~55%)[1]
Pregnancy
Widely used in pregnancy for HSV/VZV indications; reassuring registry data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Acyclovir is selectively phosphorylated to acyclovir monophosphate by viral thymidine kinase in HSV/VZV-infected cells, then by host kinases to acyclovir triphosphate, a chain-terminating inhibitor of viral DNA polymerase with markedly higher affinity for the viral than host enzyme.0 The viral-kinase-only initial phosphorylation step is the source of selectivity; uninfected cells generate minimal active drug. Dose-adjust by renal function; rare crystalline nephropathy with rapid IV bolus (slow IV infusion mitigates)[1]. Valacyclovir, the L-valyl ester prodrug, provides higher oral bioavailability and a more convenient dosing schedule for outpatient use.
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Zovirax (acyclovir), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018828s041,019909s029,020089s022lbl.pdf